HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study.

AbstractBACKGROUND:
The aim of this study was to test for differences in cancer specific mortality (CSM) rates between radical nephrectomy (RN) and partial nephrectomy (PN) in pT3a nmRCC patients.
METHODS:
Within the surveillance, epidemiology, and end results database (2005-2016), 13,177 pT3a patients treated with either PN or RN were identified. Before and after 1:2 ratio propensity score (PS)-match between PN and RN patients, cumulative incidence plot and competing risks regression (CRR) were used to test differences in CSM and other cause mortality (OCM) rates.
RESULTS:
Relative to PN (N.=1615, 22.5%), RN patients harbored higher tumor size (72 vs. 38 mm; >70 mm 51 vs.10%), of more aggressive histology, collecting duct (0.4 vs. 0.2%) and sarcomatoid (2.3 vs.0.8%), of higher grade (51.0 vs. 37.5%). After PS-matching and OCM adjustment, 5-year CSM was 3-fold higher after RN than PN (P<0.01). Similarly, after PS matching and CSM adjustment, also 5-year OCM rates were higher after RN (HR: 1.59, P=0.0003).
CONCLUSIONS:
PN does not appear to compromise the oncological outcomes in patients with pT3a or high-grade renal masses when compared with RN. Therefore, these concerns should not deter a surgeon from attempting PN when otherwise technically feasible.
AuthorsAngela Pecoraro, Daniele Amparore, Matteo Manfredi, Federico Piramide, Enrico Checcucci, Zhe Tian, Dario Peretti, Cristian Fiori, Pierre I Karakiewicz, Francesco Porpiglia
JournalMinerva urology and nephrology (Minerva Urol Nephrol) Vol. 74 Issue 4 Pg. 445-451 (Aug 2022) ISSN: 2724-6442 [Electronic] Italy
PMID35147387 (Publication Type: Journal Article)
Topics
  • Carcinoma, Renal Cell (pathology, surgery)
  • Humans
  • Kidney Neoplasms (pathology)
  • Nephrectomy (methods)
  • Propensity Score
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: